A pregnant woman collapses in a hospital in the Kasai Province of the Democratic Republic of the Congo. High fever. Bloody diarrhoea. Haemorrhage. She dies five days later. Within weeks, the WHO confirms another Ebola outbreak. Three months after that, a new, deadlier variant crosses an international border and lands in a capital city. The world is, once again, on edge.

There is no virus on earth that commands quite the same visceral dread as Ebola. It kills fast, it kills visibly, and it kills in some of the most fragile corners of the planet — corners where war, poverty, and broken health systems conspire to let it burn unchecked. And in May 2026, after decades of outbreaks that each seemed to be contained just in time, the World Health Organization made the announcement that global health experts had long feared: a new strain of Ebola virus disease spreading across the Democratic Republic of the Congo and Uganda has been declared a public health emergency of international concern (PHEIC) — the organization's highest level of alert short of a pandemic emergency. Understanding how we got here, what the virus actually does, and why it keeps returning requires going all the way back to the beginning.

The story of Ebola begins in the autumn of 1976, in a dense stretch of equatorial forest in northern Zaire — now the Democratic Republic of the Congo — near a small tributary of the Congo River called the Ebola. A man arrived at the Yambuku Mission Hospital complaining of what seemed, to the Belgian nursing staff, like a routine case of malaria. He received an injection and was sent home. He was dead within days, and whatever had killed him was already moving. In September of that year, the virus tore through the village of Yambuku, infecting 318 people and killing 90 percent of them before disappearing as suddenly as it had arrived. Simultaneously, a near-identical hemorrhagic illness was killing workers in a cotton factory in Nzara, in what is now South Sudan. Blood samples were rushed to laboratories in Atlanta and Antwerp, where researchers identified a terrifying new pathogen — a long, thread-like structure that bore a resemblance to the Marburg virus but was genetically distinct. They named it after the river near where it first surfaced. The Ebola virus had announced itself to the world.

What researchers would spend the next half-century trying to understand is where exactly it came from. Ebola is a zoonotic virus, meaning it lives in an animal reservoir and only occasionally spills over into human populations through what scientists call a "zoonotic spillover event." The leading suspects for the natural host — the animal in which the virus circulates without causing serious illness — are the fruit bats of the family Pteropodidae, which range widely across equatorial Africa. These bats roost in the forest canopy, share fruit with primates and forest antelopes, and leave behind virus-laden droppings that humans can encounter when they venture into the bush to hunt, farm, or forage. Intermediate hosts matter too: chimpanzees, gorillas, and forest antelopes like duikers can become infected through contact with bats and serve as amplifying bridges to people. A hunter who butchers an infected animal, a child who handles a dead fruit bat found on the forest floor, a family that eats bushmeat bought from a local market — these are the moments when the virus crosses its most critical border and enters the human body for the first time. As the UK Health Security Agency has noted, while non-human primates have been a source of infection in previous outbreaks, they are considered incidental rather than reservoir hosts because they typically develop fatal illness themselves and cannot maintain the virus long-term.

Once inside a human being, the Ebola virus — a member of the filovirus family, related to the equally lethal Marburg virus — launches a devastatingly efficient assault on the body's defenses. It targets immune cells first, hitching a ride inside macrophages and dendritic cells to spread throughout the lymphatic system before attacking the vascular endothelium, the lining of blood vessels. The incubation period, the silent window between infection and the appearance of symptoms, ranges from two to 21 days, though it typically falls between seven and eleven days. During this time, a person carries the virus but is not yet infectious — they cannot transmit it to others. The critical danger point arrives with the first symptoms. What begins as a sudden, violent fever, crippling fatigue, and intense muscle pain rapidly evolves, within days in severe cases, into vomiting, diarrhoea, rash, impaired kidney and liver function, and — in the hemorrhagic stage that gave the disease its original name of "hemorrhagic fever" — internal and external bleeding. The case-fatality rate for the most common Zaire strain has ranged from 25 percent to 90 percent across different outbreaks, with an average of about 50 percent. Death, when it comes, typically results from massive fluid loss, septic shock, and multi-organ failure.

The virus spreads person-to-person exclusively through direct contact with the blood, secretions, organs, or bodily fluids of an infected individual — or with surfaces and materials contaminated by these fluids. It does not spread through the air. It cannot survive for long on dry surfaces. It is not transmitted through casual contact. These biological facts should make it, in theory, containable. The tragedy of every major Ebola outbreak in history is the gap between that theoretical containability and the social, cultural, and structural realities that consistently allow the virus to outrun even well-intentioned responses. Traditional burial practices, in which mourners wash and touch the body of the deceased, have been a persistent driver of transmission in outbreak after outbreak. Healthcare facilities with inadequate infection control — poorly sterilized needles, insufficient personal protective equipment, overwhelmed staff — have time and again functioned as amplifiers rather than barriers. The 1976 Yambuku outbreak itself was partly spread by the mission hospital, where five syringes were reused between patients every morning without proper sterilization between uses. The virus found its most efficient early vehicle not in the jungle but in the clinic.

Between 1979 and 1994, no human Ebola cases were detected anywhere in the world. Researchers assumed, with some relief, that the virus was geographically limited and biologically constrained. Since 1994, however, outbreaks have been recognized with increasing frequency, and the intervals between them have grown shorter. There were outbreaks in Gabon in 1994 and 1996, in South Africa in 1996, in Uganda in 2000, in the DRC in 2007. Each was contained, eventually. But each also revealed the same systemic vulnerabilities: remote geography, fragile health infrastructure, community distrust of outside responders, and the terrifying speed with which a single index case — a single infected person who reaches a hospital, attends a funeral, travels to a market town — can seed chains of transmission across a wide area before anyone realizes what is happening.

Nothing in the preceding decades prepared the world for what began, almost invisibly, in a small forested village in southeastern Guinea in December 2013. A two-year-old boy named Emile Ouamouno fell ill with what his family thought was a common illness. He died on December 28. His mother, sister, and grandmother followed him within weeks. Retrospective case-finding by the WHO would later identify Emile as the index case of the worst Ebola epidemic in recorded history. By the time international alarm bells sounded in March 2014, the virus had already crossed from Guinea into Liberia. By July, it had reached the capitals of all three countries — Conakry, Monrovia, and Freetown — cities with combined populations in the millions, airports connected to the global air network, and health systems that had been gutted by decades of poverty and civil war.

The 2014–2016 West African Ebola epidemic was, by every measure, unprecedented. More than 28,600 people were infected. More than 11,325 died. It was the first time Ebola had broken out of its traditional niche in Central Africa, the first time it had taken hold in major urban centers, and the first time it resulted in imported cases reaching multiple continents, including the United States, Spain, Italy, and the United Kingdom. It was also the first time that cases and deaths in this single outbreak exceeded the combined toll of every previous Ebola outbreak since 1976. The epidemic was described using superlatives across every dimension: largest, deadliest, longest, most geographically dispersed. And it was allowed to grow to those catastrophic dimensions in part because of a delayed international response that, by the time it arrived, was already chasing a wildfire.

The WHO declared the outbreak a Public Health Emergency of International Concern on August 8, 2014, several months after Médecins Sans Frontières had begun raising emergency alarms that went unheeded. On September 18, 2014, the United Nations Security Council took the extraordinary step of adopting Resolution 2177, declaring the outbreak a "threat to international peace and security" — the first time in the Security Council's history that it had ever adopted a resolution focused on a public health crisis. On the same day, the UN Secretary-General established UNMEER, the UN Mission for Ebola Emergency Response, the first health-specific mission ever created by the United Nations, headquartered in Accra, Ghana, to coordinate the resources of all UN agencies and international partners. Despite the mobilization, a report by Save the Children later found that organizations working in the field struggled to translate the arriving resources into efficient action, hampered by bureaucratic delays, a lack of community trust, and the sheer logistical challenge of operating in three countries simultaneously. An estimated 11,000 additional deaths from malaria, HIV, and tuberculosis occurred in the three affected countries in 2014 alone as Ebola swallowed health system capacity and scared patients away from clinics. The epidemic was finally declared over by the WHO on June 9, 2016, but its aftermath reshaped global health governance permanently.

Among the most consequential changes the West African epidemic forced were institutional reforms within the WHO itself. The WHO Health Emergencies Programme was established on July 1, 2016, at the request of the World Health Assembly, to give the organization faster, better-resourced outbreak response capacity. The Joint External Evaluation process was introduced to independently assess countries' health security capabilities. National Action Plans for Health Security were created as roadmaps for building those capacities. And the race to develop vaccines — which had languished for decades because the markets were too small and too poor to attract pharmaceutical investment — suddenly became a global priority.

The fruits of that accelerated research effort appeared in 2019, when rVSV-ZEBOV, sold under the brand name Ervebo, became the first licensed Ebola vaccine, approved by both the European Medicines Agency and the US Food and Drug Administration. Developed by Merck and field-tested during the DRC's devastating 2018–2020 outbreak — the second-largest Ebola outbreak ever recorded, centered in the conflict-ridden provinces of North Kivu and Ituri — Ervebo uses a live attenuated recombinant vesicular stomatitis virus engineered to express the glycoprotein of the Zaire ebolavirus. Deployed in a "ring vaccination" strategy — vaccinating all known and likely contacts of confirmed cases — it proved highly effective against the Zaire strain. The DRC's 2018–2020 outbreak killed more than 2,000 people and coincided with active armed conflict, attacks on healthcare workers, and community resistance that made response operations extraordinarily dangerous. But Ervebo helped contain it.

The critical limitation of Ervebo, which defines much of the current crisis, is that it protects only against the Zaire strain. There are six known species of Orthoebolavirus that can infect humans: Ebola virus (Zaire), Sudan virus, Bundibugyo virus, Taï Forest virus, Reston virus, and Bombali virus. The vast majority of documented large outbreaks have been caused by Zaire, but Sudan and Bundibugyo have each triggered deadly epidemics of their own. As the WHO's own fact sheets note, while licensed vaccines and therapeutics exist for Ebola virus disease caused by the Zaire strain, there is no approved vaccine or treatment for other Ebola diseases, including Sudan virus disease and Bundibugyo virus disease. Candidate products are in development, but none has yet received regulatory approval.

This gap became immediately, horrifyingly relevant when a new outbreak was declared in the DRC's Kasai Province on September 4, 2025. The index case was a pregnant woman who presented at Bulape General Reference Hospital on August 20, 2025 with high fever, bloody diarrhoea, haemorrhage, and extreme weakness. She died five days later from multiple organ failure. Laboratory testing confirmed the Zaire strain of Ebola virus. Whole-genome sequencing established that this was a new zoonotic spillover event — not a continuation of any previous outbreak — representing nature's persistent, indifferent tendency to reintroduce the virus from its animal reservoir into human populations. WHO situation reports documented the outbreak spreading across six health areas in Bulape Health Zone, with 64 confirmed and probable cases and 42 deaths by late September — an overall case fatality ratio of 65.6 percent. Females accounted for 57.8 percent of cases, and children under ten years of age represented a quarter of all infections and nearly a third of all deaths. Signs of containment emerged by early October 2025, with 1,985 contacts under follow-up and no new cases for ten consecutive days. The outbreak was eventually declared over in December 2025, the 16th Ebola outbreak the DRC had endured since 1976.

The world barely had time to exhale before the 17th began. On May 5, 2026, the WHO was alerted to a high-mortality outbreak of unknown illness in Mongwalu Health Zone, Ituri Province, eastern DRC, including deaths among healthcare workers. Ituri Province is not an abstraction on a map — it is one of the most conflict-affected territories on earth, home to 1.9 million people in need of humanitarian assistance, a region where armed groups operate freely, where refugee movements across borders are constant, and where miners travel in and out of remote gold-mining areas carrying commerce, culture, and now, a virus. On May 14, laboratory analysis confirmed Bundibugyo virus disease in eight of thirteen blood samples from Rwampara Health Zone. The DRC's Ministry of Health officially declared the country's 17th Ebola outbreak on May 15, 2026. Within 24 hours, Uganda confirmed two separate imported cases in its capital, Kampala — a Congolese man who died in a Kampala hospital, and a second case detected the following day with no apparent link to the first, suggesting the virus was moving independently along multiple travel pathways.

On May 16, 2026, WHO Director-General Tedros Adhanom Ghebreyesus determined that the epidemic constituted a public health emergency of international concern — the PHEIC designation, the organization's highest and rarest alert level. As of May 16, WHO reported eight laboratory-confirmed cases, 246 suspected cases, and 80 suspected deaths in Ituri Province, spread across the health zones of Bunia, Rwampara, and Mongwalu. Africa CDC put the numbers higher, at 336 suspected cases and 87 deaths by May 17. The CDC confirmed that this was the DRC's 17th Ebola outbreak since 1976 and only the third time the Bundibugyo strain had ever been detected in humans — the previous two occurrences being in Uganda between 2007 and 2008, and in the DRC in 2012.

The Bundibugyo strain is in some ways a crueler challenge than the Zaire strain precisely because it is rarer and less studied. Its case fatality rate has historically ranged between 25 percent and 50 percent — lower than Zaire at its worst, but no less lethal at scale, and compounded by the complete absence of licensed countermeasures. No approved vaccine or therapeutic exists for Bundibugyo virus disease. Researchers have discussed the possibility of deploying Ervebo — the Zaire-strain vaccine — off-label, but an animal study suggesting partial cross-protection against Bundibugyo comes with significant caveats about both effectiveness and safety when a vaccine engineered for one viral glycoprotein is used against a genetically distinct relative. The PHEIC declaration was, in part, driven by this therapeutic vacuum, which the WHO described as a key reason the event qualifies as extraordinary under the terms of the International Health Regulations.

What makes the 2026 Ituri outbreak so alarming is the same constellation of factors that has complicated every DRC Ebola response since 2018: active armed conflict, massive population displacement, and the extraordinary mobility of communities in a region defined by trade, mining, and cross-border movement. The Africa CDC noted that the first cases were reported in Mongwalu, a high-traffic gold-mining area in Ituri Province, from which they migrated to Rwampara and Bunia health zones as patients sought medical care — each seeking help and each, unwittingly, seeding new transmission chains. Miners travel to Kampala. Refugees cross into Uganda and South Sudan. The DRC-Rwanda border, a historically porous trade corridor, has been subjected to heightened screening. Ituri's status as a commercial and migratory hub greatly increases the risk of the disease spreading to the broader region, and the ongoing conflict means that healthcare workers attempting contact tracing have literally been attacked in the field. WHO Director-General Tedros said he was "deeply concerned about the scale and speed" of the outbreak, noting that the true number of cases was potentially far larger than what had been reported.

At least four healthcare workers at the same hospital have died, which carries a specific and terrible significance: when healthcare workers become patients, the health system itself becomes a vector. Facilities that should be treating victims instead become sources of infection, driving patients and their families away from care precisely when early hospital admission — which dramatically improves survival through supportive hydration and symptom management — could save lives. Vinod Balasubramaniam, a molecular virologist at Monash University, has noted that when healthcare workers are affected, the health system's own vulnerability accelerates an outbreak in ways that community-level transmission alone cannot. History repeatedly bears this out. The 1976 Yambuku outbreak. The 1995 Kikwit outbreak in the DRC. Multiple healthcare-associated clusters in the 2014–2016 epidemic. And now Ituri, 2026.

Infections have been reported among individuals with no traceable connection to each other, suggesting either multiple, independent exposure events in the field — consistent with an ongoing zoonotic spillover in an area with dense human-wildlife interfaces — or a level of undetected community transmission that surveillance systems have not yet captured. The WHO's PHEIC declaration is not a prediction of pandemic spread; it explicitly does not meet the organization's criteria for a pandemic emergency, and the WHO advises against closing international borders. Rather, it is a mobilization signal — a legal and political instrument under the International Health Regulations designed to compel donor agencies, neighboring countries, and international organizations into action, to unlock emergency funding, and to trigger coordinated scientific, logistical, and diplomatic responses before the window for containment closes.

Whether that mobilization arrives swiftly enough is the question that haunts every Ebola response. The lesson of 2014 — the defining Ebola lesson of our era — is that delay is measured in bodies. Médecins Sans Frontières raised alarms about the Guinea outbreak for months before the international community recognized the scale of what was unfolding. The international response did not begin in earnest until September 2014, when the UN created UNMEER, by which point the epidemic had been burning for nine months and was accelerating toward a catastrophic peak. The subsequent reforms to WHO's emergency response capacities were intended to prevent that lag from ever recurring. But the 2026 outbreak tests those reforms against the hardest possible scenario: a novel viral strain, no licensed vaccine, active conflict, and a region of extraordinary human mobility at the intersection of three countries' borders.

The biological facts of Ebola transmission — the requirement for direct bodily fluid contact, the absence of airborne spread — mean that the virus can theoretically always be stopped with rigorous contact tracing, isolation, safe burial practices, and personal protective equipment. These are not exotic technologies. They are, in principle, available. What has never been reliably available in every Ebola-affected community is the infrastructure, trust, and political stability that allow these measures to be applied consistently. Community engagement — the work of earning trust, translating medical instructions into culturally resonant guidance, and turning local leaders into response partners rather than obstacles — has been identified by every post-outbreak review as the decisive variable between outbreaks that are contained quickly and those that are not. The WHO's response framework emphasizes community engagement alongside contact tracing, ring vaccination where possible, safe and dignified burial practices, and laboratory support as the core pillars of any Ebola response.

The Bundibugyo crisis of 2026 arrives at a moment when the world has more tools than it has ever had to fight Ebola — and, simultaneously, faces more structural vulnerabilities than perhaps any previous outbreak period. Climate change is expanding the range of fruit bat habitats, potentially bringing reservoir populations into closer contact with human settlements. Deforestation and agricultural encroachment push human communities deeper into ecosystems where spillover risks are highest. The COVID-19 pandemic exposed, in devastating detail, how global health infrastructure can be overwhelmed and how disinformation can undermine even the most straightforward public health messaging. Conflict — in the DRC, in the broader Great Lakes region, across a swath of sub-Saharan Africa — destroys health systems faster than they can be rebuilt and displaces populations into precisely the kinds of conditions that allow infectious diseases to find new hosts.

There is also the matter of what might be called the vaccination gap — the uneven global distribution of protective immunity that leaves entire populations exposed to pathogens for which, in wealthier countries, countermeasures already exist or could be rapidly developed. The mpox emergency declared by the WHO in 2024 offers an instructive precedent: experts noted at the time that the declaration did little to rapidly deliver diagnostics, medicines, and vaccines to affected African countries, raising hard questions about the real-world impact of PHEIC designations when supply chains, manufacturing capacity, and political will remain misaligned. For Bundibugyo, the challenge is even more acute, because no approved vaccine exists at all. Accelerating the development and regulatory approval of pan-Ebola vaccines — candidates that could offer cross-strain protection rather than immunity to only one species of the virus — has become an urgent scientific and political priority.

The CDC has implemented enhanced public health screening for travelers arriving in the United States from the DRC, Uganda, and South Sudan, alongside traveler monitoring programs for individuals from affected regions. The risk to the United States and other high-income countries remains, as public health authorities consistently note, low — the virus does not spread through casual contact, and modern healthcare facilities with proper infection control are well-positioned to prevent any imported case from seeding local transmission. But "low risk" is not "zero risk," and the psychological and logistical cost of even a single imported case — the contact tracing, the quarantine, the media attention, the diversion of public health resources — is sufficient to keep health ministries worldwide paying very close attention to Ituri Province.

Ebola's story is, at its deepest level, a story about the relationship between human civilization and the natural world — and about how that relationship, strained by deforestation, urbanization, conflict, and ecological disruption, produces moments of dangerous proximity between species that should, in any balanced ecosystem, remain apart. The virus did not evolve to infect humans. It exists in bats and perhaps other animals in an evolutionary equilibrium that causes no visible harm to its reservoir hosts. Every human Ebola case is an accident — a spillover, a contaminated needle, a funeral, a butchered carcass — that need never have happened. And yet, 50 years after the world first learned the name Ebola, those accidents keep happening with increasing frequency, each one carrying the potential to cascade into the kind of catastrophic epidemic that the 2014–2016 West African outbreak demonstrated is entirely possible in a connected world.

The question is no longer whether Ebola will keep returning. It will. The WHO's own disease outbreak news confirms that whole-genome sequencing of the 2025 Kasai outbreak showed it to be a fresh zoonotic spillover event with no link to previous outbreaks — nature introducing the virus anew, independently, as it likely has been doing for millennia. The question is whether the world will, in the years between outbreaks, build the health systems, the community trust, the surveillance networks, the vaccine portfolios, and the political commitments needed to contain the next one before it becomes the one that finally escapes. As of May 21, 2026, with the Bundibugyo strain spreading through conflict-torn eastern Congo and cases turning up in Uganda's capital without obvious epidemiological links, that question is not hypothetical. It is urgent, live, and unanswered.

---

Sources and further reading: WHO Ebola disease fact sheet | WHO PHEIC declaration May 2026 | WHO 2025 DRC outbreak report | CDC Ebola current situation | CDC outbreak history | WHO West Africa 2014–2016 emergency | Africa CDC | Doctors Without Borders / MSF